Navigation Links
Accuri Cytometers Announces Commercial Launch of Revolutionary Accuri C6 Flow Cytometer(TM) System

- Bench-Top Flow Cytometer Delivers Performance and Features Similar to Market-Leading Systems in an Easy-to-Use, Accessible and Affordable Format


- See the C6 Flow Cytometer in San Diego at the Accuri Booth at

Experimental Biology 2008 and at AACR 2008 -

ANN ARBOR, Mich., April 7, 2008 /PRNewswire/ -- Accuri Cytometers, Inc. today announced the commercial launch of the Accuri C6 Flow Cytometer(TM) System, designed to bring the power of flow cytometry cell analysis to the laboratory of every life sciences researcher. The Accuri C6 is a bench-top system that delivers performance and features similar to those of the market-leading flow cytometers, yet it is easy even for novice users to set up and operate. The radical redesign that produced the Accuri C6 has also made possible a dramatic reduction in price-with the system selling for a fraction of the cost of most flow cytometers.

"The commercial availability of the Accuri C6 Flow Cytometer System is potentially transformative, since researchers increasingly rely on data that only flow cytometry can provide, yet most scientists currently lack routine access to this technology," said Dr. Larry A. Sklar, professor of pathology at the University of New Mexico Medical School and head of the National Institutes of Health-funded Molecular Libraries Screening Center. "The availability of easy-to-use, high-quality flow cytometers at the researcher's bench should enable far greater use of flow cytometry, resulting in many new applications for biomedical research."

The Accuri C6 Flow Cytometer System is a full-featured, two-laser, six-detector analytical system that includes the C6 Flow Cytometer, CFlow Software and a PC. The C6 Flow Cytometer System has detectors to capture both forward and side-scattered light, as well as four fluorescent detectors equipped with user-replaceable optical filters. The operating software is designed to make data collection and analysis fast and hassle-free.

"Our goal in creating the Accuri C6 System was to produce a high- performance cell analysis system that could bring the power of flow cytometry into the labs of life sciences researchers everywhere," said Jennifer Baird, CEO of Accuri. "We believe that the system we are commercially launching today achieves that ambitious goal. Developed by an interdisciplinary team with no pre-conceived ideas about flow cytometry, the C6 combines novel technology and software with simplicity of design and high-quality components to achieve performance similar to the leading flow cytometers, but with true ease-of-use, a bench-top footprint and a price affordable by virtually any laboratory."

Accuri completely redesigned the hardware, user interface and analysis software of the C6 system with input from both researchers who use flow cytometry on a regular basis and those whose use have been limited by lack of access. The company teamed with Ann Arbor-based software firm Menlo Innovations, which brought its unique, award-winning methods to the development of the Accuri system's easy-to-use analysis software, a critical component of the approach. Accuri's innovations, coupled with its state of the art components, result in a cytometer that is powerful, robust, compact and affordable. The C6 Flow Cytometer works with all existing reagents and protocols, making the transition from current flow cytometers seamless.

"As a biomedical scientist I am acutely aware of how important flow cytometry is for my lab's research, yet the wait for access to a flow cytometer was often a major bottleneck to our progress," said Dr. Peter Smith, a researcher at Innovative BioTherapies, a biotechnology company developing a wearable artificial kidney. "I was therefore eager to serve as an early evaluator for the Accuri C6 Flow Cytometer System. Imagine my delight when, as a less experienced user, I was able to have the system running experiments within an hour of taking it out of the box. The hands-off simplicity and ease-of-use of the C6 system are liberating. The ability to conduct high- quality flow cytometry analyses simply and inexpensively whenever we need them will have a positive impact on the productivity of our lab."

Among the first major biomedical research institutions already using the Accuri C6 Flow Cytometer System are the University of California at San Francisco, Harvard University, the Medical University of South Carolina, the University of Michigan, the University of New Mexico and the University of Pittsburgh.

Accuri's chief commercial officer Jack Ball noted, "Initial response to the C6 Flow Cytometer System has been extremely encouraging, reflecting the pent-up demand for accessible, high-performance cell analysis tools in our initial target market--researchers currently using flow cytometers but frustrated by access limitations. Early access beta test users have been very positive, and every researcher we speak with reports that a flow cytometer that delivers on our performance specifications and is easy-to-use would find ready acceptance in their labs. With this formal market launch, we now look forward to fulfilling that demand."

Explicitly designed for routine use by biomedical researchers in their own labs, the Accuri C6 Flow Cytometer(TM) is a full featured bench-top cell and bead analysis system. For more information about Accuri and the C6 Flow Cytometer series, visit

Accuri C6 Full Featured Flow Cytometer SystemFeatures

-- Blue & red lasers (488nm & 640nm)

-- 4 fluorescent channels

-- 2 scatter channels (forward & side)

-- User adjustable core size and flow rate

-- 6 decades of digital dynamic range

-- Software that is intuitive & easy to operate

-- Small size

-- Easily portable


-- Compatible with popular reagents, kits & protocols

-- Affordable to own

-- Excellent resolution of complex cell populations

-- No lost data-no gain settings to adjust

-- No user training required

-- Simple start-up guide has most running in minutes

-- Uncompromising results at a great value

-- Saves valuable bench space

Come see how you can have Cell Analysis Within Reach(TM). Visit the Accuri booth at:

-- Experimental Biology 2008, San Diego, CA, April 5-9, 2008, Booth 1215.

-- AACR Annual Meeting 2008, San Diego, CA, April 12-16, 2008, Booth 1731.

About Accuri Cytometers

Accuri Cytometers, Inc. is an Ann Arbor-based life sciences company developing and marketing revolutionary high performance cell analysis systems designed to bring the power of flow cytometry into the labs of life sciences researchers everywhere. Reflecting the input of hundreds of researchers, the Accuri C6 Flow Cytometer(TM) is a full featured bench-top cell and bead analysis system that provides similar capabilities to those of industry- leading flow cytometers in an easy-to-use format and at a fraction of their cost. The Accuri system was engineered from the start to be compact, powerful and user-friendly, while also being affordable by most research laboratories. For more information, visit


Accuri Cytometers: Media:

Jack Ball Barbara Lindheim

Chief Commercial Officer GendeLLindheim BioCom Partners

(734) 994-8000 (212) 918-4650

SOURCE Accuri Cytometers, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
2. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index (As Revised)
3. Smart Balance Announces Sales Organization Appointments
4. Global Action Board of Directors Announces Addition of Newest Member, Robert Hernreich
5. NTMir Announces First International Research Grant for Genome Sequencing
6. Dialysis Corporation of America Announces the Development of a New Facility in Pennsylvania
7. SurgiQuest Announces First Procedure Using AirSeal(TM) Access System
8. Zimmer Announces Actions Affecting its Ohio-based Orthopaedic Surgical Products Operation
9. Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
10. NUCRYST Announces Senior Management Change
11. Renovis Announces Expiration of Hart-Scott-Rodino (HSR) 30-Day Waiting Period; Merger With Evotec on Track to Close in Early May, 2008
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: